Compare ICG & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ICG | NRXS |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.4M | 82.0M |
| IPO Year | 2022 | 2023 |
| Metric | ICG | NRXS |
|---|---|---|
| Price | $1.43 | $4.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $2.00 | ★ $11.00 |
| AVG Volume (30 Days) | ★ 282.3K | 115.6K |
| Earning Date | 11-27-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,569,282.00 |
| Revenue This Year | N/A | $118.53 |
| Revenue Next Year | $109.44 | $101.28 |
| P/E Ratio | $6.80 | ★ N/A |
| Revenue Growth | N/A | ★ 32.89 |
| 52 Week Low | $0.60 | $2.21 |
| 52 Week High | $2.28 | $9.33 |
| Indicator | ICG | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 59.34 | 27.47 |
| Support Level | $1.41 | N/A |
| Resistance Level | $1.52 | $7.79 |
| Average True Range (ATR) | 0.08 | 0.57 |
| MACD | -0.01 | -0.21 |
| Stochastic Oscillator | 75.00 | 5.62 |
Intchains Group Ltd is an inventive altcoins development company that engages in the provision of altcoin mining products, the strategic acquisition and holding of Ethereum-based cryptocurrencies and the active development of inventive Web3 applications. The company offers high-performance mining products including altcoin mining machines incorporating its ASIC chips that have high computing power and superior power efficiency, ASIC chips and ancillary software and hardware, all of which cater to the evolving needs of the blockchain industry. Geographically, it operates in Mainland China, Hong Kong, and Other countries or regions.
Neuraxis Inc is a growth-stage medical technology company focused on neuromodulation therapies for chronic and debilitating conditions in the gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).